Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chris Harbron

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Plos One|February 13, 2026
Prognostic pan-cancer and single-cancer models: A large-scale analysis using a real-world clinico-genomic databaseSarah F McGough, Svetlana Lyalina, Devin Incerti, et al.
Cancer Biomarkers : Section a of Disease Markers|November 19, 2015
Expression of potential biomarkers associated with homologous recombination repair in patients with ovarian or triple-negative breast cancerHiroyuki Nomura, Fumio Kataoka, Daisuke Aoki, et al.
Nature Medicine|June 30, 2022
Systematic pan-cancer analysis of mutation-treatment interactions using large real-world clinicogenomics dataRuishan Liu, Shemra Rizzo, Sarah Waliany, et al.
Cancer Reports (Hoboken, N.J.)|January 25, 2022
Real-world data prognostic model of overall survival in patients with advanced NSCLC receiving anti-PD-1/PD-L1 immune checkpoint inhibitors as second-line monotherapyCristina Julian, Robson J M Machado, Sandhya Girish, et al.
British Journal of Cancer|July 1, 2017
Embracing model-based designs for dose-finding trialsSharon B Love, Sarah Brown, Christopher J Weir, et al.
The AAPS Journal|April 22, 2022
Machine Learning Prediction of Clinical Trial Operational EfficiencyKevin Wu, Eric Wu, Michael DAndrea, et al.
Leukemia|August 30, 2019
MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trialChristiane Pott, Laurie H Sehn, David Belada, et al.
BMC Medical Informatics and Decision Making|May 1, 2026
The 'Hippocratic Oath' for AI-based clinical decision support systemsSolomon Bracey, Ben Ainsworth, Joseph Alderman, et al.
Virchows Archiv : an International Journal of Pathology|January 29, 2013
Validation of the BRCA1 antibody MS110 and the utility of BRCA1 as a patient selection biomarker in immunohistochemical analysis of breast and ovarian tumoursRoy Milner, Helen Wombwell, Sonia Eckersley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 14, 2023
Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM StudyChristiane Pott, Vindi Jurinovic, Judith Trotman, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Plos One|February 13, 2026
Prognostic pan-cancer and single-cancer models: A large-scale analysis using a real-world clinico-genomic databaseSarah F McGough, Svetlana Lyalina, Devin Incerti, et al.
Cancer Biomarkers : Section a of Disease Markers|November 19, 2015
Expression of potential biomarkers associated with homologous recombination repair in patients with ovarian or triple-negative breast cancerHiroyuki Nomura, Fumio Kataoka, Daisuke Aoki, et al.
Nature Medicine|June 30, 2022
Systematic pan-cancer analysis of mutation-treatment interactions using large real-world clinicogenomics dataRuishan Liu, Shemra Rizzo, Sarah Waliany, et al.
Cancer Reports (Hoboken, N.J.)|January 25, 2022
Real-world data prognostic model of overall survival in patients with advanced NSCLC receiving anti-PD-1/PD-L1 immune checkpoint inhibitors as second-line monotherapyCristina Julian, Robson J M Machado, Sandhya Girish, et al.
British Journal of Cancer|July 1, 2017
Embracing model-based designs for dose-finding trialsSharon B Love, Sarah Brown, Christopher J Weir, et al.
The AAPS Journal|April 22, 2022
Machine Learning Prediction of Clinical Trial Operational EfficiencyKevin Wu, Eric Wu, Michael DAndrea, et al.
Leukemia|August 30, 2019
MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trialChristiane Pott, Laurie H Sehn, David Belada, et al.
BMC Medical Informatics and Decision Making|May 1, 2026
The 'Hippocratic Oath' for AI-based clinical decision support systemsSolomon Bracey, Ben Ainsworth, Joseph Alderman, et al.
Virchows Archiv : an International Journal of Pathology|January 29, 2013
Validation of the BRCA1 antibody MS110 and the utility of BRCA1 as a patient selection biomarker in immunohistochemical analysis of breast and ovarian tumoursRoy Milner, Helen Wombwell, Sonia Eckersley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 14, 2023
Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM StudyChristiane Pott, Vindi Jurinovic, Judith Trotman, et al.
Pageof 4